Holdco Nuvo Group D G Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Holdco Nuvo Group D G Ltd (NUVO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Holdco Nuvo Group D G Ltd vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 110M combined for tracked competitors (0.2% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+74.1%) for its tracked peer group.
- Profitability: Its 0.0% net margin compares with -13.1% for the peer group.
- Peer revenue share: Holdco Nuvo Group D G Ltd accounted for 0.4% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
NUVO Sales vs. its Competitors, Q4 2023
With a net margin of 0.00 %, Holdco Nuvo Group D G Ltd achieved higher profitability than its competitors (-13.08 %).
Holdco Nuvo Group D G Ltd generated 0.37 % of the combined sales of its peer group.
Holdco Nuvo Group D G Ltd vs. its Competitors, Q4 2023
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Holdco Nuvo Group D G Ltd and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Holdco Nuvo Group D g Ltd | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Holdco Nuvo Group D G Ltd's competitor groups requires a Commercial License.
Holdco Nuvo Group D G Ltd's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Holdco Nuvo Group D g Ltd | - | - | - | - |
| Competitors combined (5) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NUVO Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Avadel Pharmaceuticals Plc | 282.9% | Outperformed |
| 2 | Nutriband Inc | 282.9% | Outperformed |
| 3 | Prf Technologies Ltd | 282.9% | Outperformed |
| 4 | Zynex inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Holdco Nuvo Group D G Ltd's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Holdco Nuvo Group D G Ltd's Comment on Competition and Industry Peers
Publicly Traded Peers of Holdco Nuvo Group D g Ltd
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Holdco Nuvo Group D g Ltd | - | 0.18 |
| Avadel Pharmaceuticals Plc | 2,189.59 | 248.76 |
| Nutriband Inc | 88.50 | 1.62 |
| Zynex inc | 3.79 | 108.25 |
| Vystar Corporation | 1.94 | 0.05 |
| Prf Technologies Ltd | 0.60 | 0.02 |
| SUBTOTAL | 2,284.41 | 358.87 |
Sources: Holdco Nuvo Group D g Ltd's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Holdco Nuvo Group D g Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Holdco Nuvo Group D G Ltd's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Avadel Pharmaceuticals Plc | Reportable 100.00 % |
| Prf Technologies Ltd | Solar By Business Segments 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Holdco Nuvo Group D G Ltd's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Holdco Nuvo Group D g Ltd | - | - | - |
| Avadel Pharmaceuticals Plc | 2,190 | 1,615,338 | -1,805 |
| Nutriband Inc | 88 | 323,536 | -1,392,589 |
| Zynex inc | 4 | 309,294 | -211,309 |
| Vystar Corporation | 2 | 48,311 | -1,358,347 |
| Prf Technologies Ltd | 1 | 2,429 | -717,429 |
| PEERS TOTAL | 2,284 | 693,807 | -169,399 |
Holdco Nuvo Group D G Ltd's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Holdco Nuvo Group D g Ltd | US 93.18 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Holdco Nuvo Group D G Ltd's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
No rule matched.
Opportunities
- A meaningful share of tracked competitors (80.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Holdco Nuvo Group D G Ltd's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Holdco Nuvo Group D g Ltd | 0.02 | 0.05 | - |
| Avadel Pharmaceuticals Plc | 1.14 | 2.76 | - |
| Nutriband Inc | 5.25 | 5.76 | 0.03 |
| Zynex inc | 0.51 | 1.15 | 14.40 |
| Vystar Corporation | 0.00 | 0.06 | - |
| Prf Technologies Ltd | 1.72 | 1.78 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Holdco Nuvo Group D G Ltd's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Holdco Nuvo Group D g Ltd | Q4 2023 | - | - |
| Avadel Pharmaceuticals Plc | Q3 2025 | +55.3 % | - |
| Nutriband Inc | Q2 2026 | -29.7 % | - |
| Zynex inc | Q3 2025 | -73.3 % | - |
| Vystar Corporation | Q1 2026 | -51.4 % | - |
| Prf Technologies Ltd | Q4 2025 | - | - |
| PEERS TOTAL | -9.0 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Holdco Nuvo Group D G Ltd's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Holdco Nuvo Group D g Ltd | Q4 2023 | - | - |
| Avadel Pharmaceuticals Plc | Q3 2025 | -33.1 % | - |
| Nutriband Inc | Q2 2026 | -45.1 % | - |
| Zynex inc | Q3 2025 | -48.1 % | -75.0 % |
| Vystar Corporation | Q1 2026 | -77.5 % | - |
| Prf Technologies Ltd | Q4 2025 | - | -84.6 % |
Holdco Nuvo Group D G Ltd's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Holdco Nuvo Group D g Ltd | - | - | - |
| Avadel Pharmaceuticals Plc | - | - | - |
| Nutriband Inc | - | - | - |
| Zynex inc | - | - | - |
| Vystar Corporation | - | - | - |
| Prf Technologies Ltd | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Holdco Nuvo Group D G Ltd's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Holdco Nuvo Group D g Ltd | - | - |
| Avadel Pharmaceuticals Plc | - | 8.80 |
| Nutriband Inc | - | 54.71 |
| Zynex inc | - | 0.04 |
| Vystar Corporation | - | 40.21 |
| Prf Technologies Ltd | - | 35.07 |
| PEERS AVERAGE | - | 6.37 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.